The Role of Montelukast in the Prevention and Treatment of Capsular Contracture (Baker Grade III-IV) - A Systematic Review and Case Analysis.

Aesthetic plastic surgery 2026

Prosenz C, Aschauer J, Thürlimann A, Oranges CM, Kalbermatten D, Montemurro P, Tremp M

관련 도메인

Abstract

[INTRODUCTION] Capsular contracture remains a significant challenge in breast implant surgery. Recent research has focused on the role of inflammatory mediators, particularly leukotrienes. The aim of this article was to conduct a systematic review of existing clinical data on an orally active selective leukotriene receptor antagonist (montelukast) and capsular contracture management in combination with surgery and to present some representative cases.

[MATERIALS AND METHODS] A meta-analysis was performed with the following keywords: "Montelukast," "Singulair," "capsular contracture," "Baker grade," and "breast implants." References from identified articles were screened to capture additional studies not retrieved through database searches (PubMed and Semantic Scholar). Moreover, we provided representative case samples in patients with Baker Grade III-IV capsular contracture undergoing surgical treatment with adjuvant montelukast treatment once daily for 90 days.

[RESULTS] Five studies with 1343 patients were included. Prophylactic montelukast reduced capsular contracture rates, particularly in Baker grade I-II cases, with statistical significance in two studies. In Baker grade III-IV contracture, montelukast had limited effect, and most patients required surgery. Extended therapy downgraded some severe cases to Baker grade II. In line with the current literature, our case examples confirmed the efficacy of montelukast with minimal side effects.

[CONCLUSION] By synthesizing available evidence, the potential of leukotriene receptor antagonism as a therapeutic adjunct to surgery for the treatment of capsular contracture is promising. The findings could pave the way for new treatment paradigms in breast implant surgery, potentially improving outcomes and patient satisfaction.

[LEVEL OF EVIDENCE V] This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online  Instructions to Authors   www.springer.com/00266 .

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
합병증 capsular contracture 피막구축 dict 7
해부 breast 유방 dict 3
해부 line scispacy 1
약물 Montelukast C0298130
montelukast
scispacy 1
약물 leukotrienes C0023545
Leukotrienes
scispacy 1
약물 leukotriene C0023545
Leukotrienes
scispacy 1
약물 Singulair C0595724
Singulair
scispacy 1
약물 [INTRODUCTION] Capsular contracture scispacy 1
질환 contracture C0009917
Contracture
scispacy 1
질환 breast implant scispacy 1
질환 Baker Grade III-IV capsular contracture scispacy 1
질환 Baker grade III-IV scispacy 1
질환 Baker grade II scispacy 1
기타 capsular scispacy 1
기타 patients scispacy 1
기타 patient scispacy 1

📑 인용 관계

이 논문이 참조한 문헌 23

외부 PMID 4건 (DB 미수집)

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문